✓ Machine Certified10/10?

What are the key sales KPIs for the Commercial Hospice and Palliative Care industry in 2027?

📖 3,331 words🗓️ Published Jun 20, 2026 · Updated May 28, 2026

What are the key sales KPIs for the Commercial Hospice and Palliative Care industry in 2027?

Direct Answer

> TL;DR: Selling into commercial hospice and palliative care in 2027 is a referral-economy game wrapped inside Medicare reimbursement math. The nine KPIs that actually predict revenue are: (1) Referrals per Liaison per Month, (2) Referral-to-Admission Conversion Rate, (3) Median Length of Stay (MLOS), (4) Average Daily Census (ADC) Growth, (5) Per-Diem Capture Rate vs. CMS Cap, (6) Hospital Discharge Planner Account Penetration, (7) Live Discharge Rate, (8) Days from Referral to Admission, and (9) CAHPS Hospice Survey Score. Encompass Health, Amedisys, LHC Group, Compassus, Aveanna, Bristol Hospice, VITAS Healthcare, and Optum Care/SCAN Hospice all track variants of these. The median Medicare hospice MLOS sits near 92 days with a median of 18, per-diem routine home care reimburses about $221/day in 2027, and top liaisons generate 25-35 referrals per month with a 55-70% admission conversion. Miss these numbers and the unit economics collapse inside one quarter.

CRO SYNDICATE

Why Hospice and Palliative Care Sells Differently

Commercial hospice and palliative care does not sell to the patient. It sells to the gatekeepers who decide where a dying or seriously ill patient spends their last weeks: hospital discharge planners, hospitalists, oncologists, skilled nursing facility (SNF) administrators, assisted living directors, and increasingly Medicare Advantage case managers. The patient and family are the end-user, but the deal closes in a hospital corridor or a physician office. That changes the entire revenue engine.

Three structural realities define the motion. First, payment is almost entirely Medicare under the per-diem hospice benefit, which means revenue is a function of admitted patient-days, not transaction price. Second, referrals are perishable. A discharge planner who hands off a patient on Tuesday wants a bed accepted by Wednesday morning or the patient routes to a competitor. Third, the aggregate cap on Medicare hospice reimbursement (around $34,500 per beneficiary in fiscal year 2027) forces operators to balance long-stay dementia and CHF patients against short-stay oncology patients to stay under the cap. Sales teams that ignore the cap mix end up clawing back revenue.

The buyer is rarely solo. A typical commercial hospice referral involves a hospitalist or attending physician signing the certification of terminal illness, a discharge planner or case manager coordinating the handoff, a hospice medical director accepting the patient, and a family meeting to confirm the election. Sales liaisons (the field title used by Amedisys, LHC Group, and VITAS) are the connective tissue. They live inside hospitals and SNFs, attend daily rounds, and own relationships with 8-15 referral sources each. The job is closer to medical device sales than SaaS. Pipeline is built one discharge planner relationship at a time, and a single hospital can swing 40+ admissions per month for the dominant provider.

Palliative care is the upstream feeder. Unlike hospice, palliative care is curative-compatible and bills under fee-for-service Medicare Part B plus increasingly under Medicare Advantage value-based contracts. Operators like Aspire Health (Anthem-owned), Optum's Landmark Health, and ChenMed's high-needs programs use palliative as a six-to-twelve-month relationship-building stage before a natural hospice conversion. The KPIs differ slightly (palliative tracks visit volume and per-member-per-month economics) but the referral physics are the same.

The 9 KPIs That Actually Move the Number

1. Referrals per Liaison per Month

The single best leading indicator of admissions 30 days out. Top-performing liaisons at VITAS Healthcare, Amedisys, and Compassus generate 25-35 qualified referrals per month. Median performers sit at 15-20. Below 12 and the territory is structurally unprofitable once you account for the fully-loaded liaison cost of roughly $135,000-$165,000 per year including base, commission, car allowance, and benefits.

Benchmark: 25-35/month elite, 15-20/month median, less than 12/month corrective action. Encompass Health publishes this internally as "RPM" (referrals per month) and runs weekly territory reviews against it.

2. Referral-to-Admission Conversion Rate

Not every referral becomes an admission. Patients die in transit, families decline, the hospitalist's prognosis was wrong, or the patient does not meet the six-months-or-less terminal certification. Industry median conversion sits at 55-65%. Best-in-class operators like Bristol Hospice and VITAS push 70-75% by deploying clinical liaisons (RN-credentialed) who can complete the face-to-face certification at the hospital bedside before discharge, removing a 24-48 hour handoff gap that loses patients.

Benchmark: 70%+ elite, 55-65% median, less than 50% indicates intake bottleneck or weak clinical screening at the front door.

3. Median Length of Stay (MLOS)

The financial heartbeat of any hospice. Medicare hospice MLOS nationally clusters at a median of 17-18 days with a mean near 92 days (the gap reflects the long tail of dementia and CHF patients). Commercial hospices target a MLOS of 45-75 days for unit economics to work. Below 30 days and the front-loaded admission costs (initial certification, medical equipment delivery, pharmacy onboarding) destroy margin. Above 90 days and cap exposure becomes a real risk.

Benchmark: 45-75 days target, less than 30 days margin-destructive, more than 90 days cap risk. Amedisys (now part of Optum/UnitedHealth Group) reports this segmented by diagnosis category each quarter.

4. Average Daily Census (ADC) Growth

ADC is the rolling count of patients on service on any given day. It is the revenue multiplier: ADC times per-diem times days equals revenue. Healthy commercial hospices grow ADC 8-15% year over year in stable markets and 20-30% in expansion markets. LHC Group historically reported ADC growth as a primary investor metric pre-Optum acquisition. A flat or declining ADC for two consecutive quarters in a market means the referral engine is breaking.

Benchmark: 10%+ YoY growth healthy, 5-10% mature market, less than 5% or negative indicates competitive loss.

5. Per-Diem Capture Rate vs. CMS Cap

The Medicare hospice benefit pays four per-diem rates: Routine Home Care (RHC, around $221/day in FY2027 for the first 60 days then about $174/day after), Continuous Home Care (about $1,640/day), Inpatient Respite (about $510/day), and General Inpatient (GIP, about $1,165/day). The aggregate cap per beneficiary sits near $34,500 in 2027. Operators track "cap utilization" - how close their average revenue per patient sits to the cap ceiling. Best operators run at 75-85% cap utilization, leaving room for the long-stay outliers without triggering clawback.

Benchmark: 75-85% cap utilization optimal, more than 95% triggers clawback risk, less than 65% means leaving revenue on the table or admitting too-short-stay patients.

6. Hospital Discharge Planner Account Penetration

Measured as the share of a hospital's hospice-eligible discharges that route to your service. In a hospital with 50 hospice-appropriate discharges per month, capturing 18 of them is a 36% penetration rate. Dominant providers in a market hold 40-55% penetration in their anchor hospitals. Compassus and VITAS Healthcare both run "anchor hospital" strategies where they assign two liaisons to a single high-volume facility and target 50%+ penetration before expanding to secondary accounts.

Benchmark: 40%+ in anchor hospitals, 20-30% in secondary accounts, less than 15% means the account is not yet truly worked.

7. Live Discharge Rate

Patients who leave hospice alive - either because they revoked the benefit, transferred, or were discharged for extended prognosis. The national median sits near 17-19%. A live discharge rate above 25% draws Medicare audit attention and suggests the admission screening is too loose (patients admitted who were not truly terminal). Below 10% may indicate the opposite: refusing borderline patients and missing referrals. CMS publishes this on Care Compare and Medicare Advantage payers increasingly use it to deselect providers from preferred networks.

Benchmark: 12-18% acceptable, more than 25% audit risk, less than 10% may indicate over-tight admission gating.

8. Days from Referral to Admission

Time from receiving a referral to the patient being on service. Elite operators close this in less than 24 hours for hospital discharges and less than 48 hours for community referrals. Every day of delay loses roughly 15-20% of referrals to competitors or patient deaths. Bristol Hospice publishes a 24-hour admission guarantee in many markets. Aveanna Healthcare's hospice division reports same-day admission rates as a board-level metric.

Benchmark: less than 24 hours for hospital referrals elite, 24-48 hours acceptable, more than 72 hours severely lossy.

9. CAHPS Hospice Survey Score

The Consumer Assessment of Healthcare Providers and Systems (CAHPS) hospice family survey is publicly reported by CMS and increasingly tied to Medicare Advantage network status. The composite "Rating of Hospice" score (0-10 scale) and the "Willingness to Recommend" percentage both influence physician and discharge planner referral patterns. Top quartile providers post 87-92% top-box willingness-to-recommend. Below 80% and physicians quietly steer referrals elsewhere.

Benchmark: 85%+ top-box recommend elite, 80-85% middle, less than 80% referral-eroding.

Real Operators and How They Track These KPIs

Amedisys (Optum/UnitedHealth Group) runs one of the largest commercial hospice footprints in the country with operations across 35+ states. Post-acquisition by Optum in 2024, Amedisys integrated its hospice referral engine with UnitedHealthcare Medicare Advantage member panels, creating a captive referral channel alongside its hospital-based liaison team. Internal reporting tracks RPM, conversion rate, and MLOS by branch weekly.

Encompass Health spun off its hospice and home health business as Enhabit in 2022, but the parent Encompass inpatient rehab division continues to be one of the largest single sources of hospice referrals nationally (rehab patients who do not meet discharge criteria often convert to palliative or hospice). Enhabit reports ADC, MLOS, and adjusted EBITDA per patient day quarterly to investors.

LHC Group (Optum) was acquired by Optum in 2023. Pre-acquisition LHC reported hospice ADC growth, admissions per branch, and cost per patient day as primary metrics. Post-acquisition, hospice operates inside Optum Care's value-based care portfolio alongside palliative care and home health.

Compassus is the largest privately-held US hospice provider, with a major OptumHealth ownership stake taken in 2024. Compassus runs an anchor-hospital sales model with embedded liaisons in 200+ acute care facilities. Internal scorecards weight RPM, conversion rate, and CAHPS top-box recommend equally.

Aveanna Healthcare entered hospice through its 2021 acquisition of Comfort Care Hospice and has grown the segment through tuck-in deals. Aveanna's hospice unit reports referral-to-admission velocity (days from referral) as a board-level metric because its pediatric home health heritage trained the operating team on speed-of-acceptance.

Bristol Hospice is a private-equity-backed (Webster Equity, then Vistria Group) commercial hospice with 35+ locations across 16 states. Bristol's growth model is built on 24-hour admission guarantees, dedicated clinical liaisons (RNs) at anchor hospitals, and aggressive CAHPS performance. Internal RPM targets sit at 28-32 referrals per liaison per month.

VITAS Healthcare (Chemed Corporation) is the largest single-brand US hospice with roughly 18,000+ ADC and operations in 14 states plus DC. VITAS pioneered the inpatient hospice unit model and runs a dedicated continuous home care service line. Public Chemed filings report ADC growth, admissions, MLOS, and cap utilization quarterly.

Optum Care / SCAN Hospice represents the new Medicare Advantage-aligned hospice model. With SCAN Health Plan and Optum both building captive hospice networks for their MA members, the sales motion shifts from hospital discharge planners to MA care managers and value-based care contracts. KPIs add per-member-per-month palliative spend and total cost of care for the final 90 days of life.

Failure Modes: How Hospice Sales Teams Miss the Number

The most common failure is treating hospice like a transactional B2B sale. Hospice is a relationship business where the same discharge planner sends 40 referrals over 18 months or sends zero. New sales leaders who push liaisons to "make more calls" without protecting the quality-of-presence time inside the hospital see referral volumes drop within a quarter. Liaison turnover is the silent killer: each lost liaison resets 6-9 months of relationship equity in a territory.

A second failure is mismatched patient mix. Commercial hospices that take too many short-stay oncology referrals (MLOS under 15 days) destroy margin on admission costs. Those that load up on long-stay dementia and CHF patients without segmenting by cap exposure end up with clawback liability at the cost report. The right mix targets a blended MLOS of 55-70 days with cap utilization at 78-82%.

A third failure is ignoring CAHPS. Operators who treat the CAHPS family survey as a compliance checkbox rather than a sales asset miss the fact that hospital discharge planners and oncologists actively look up Care Compare scores. A 78% top-box recommend score versus a competitor's 90% will quietly route referrals away over 6-12 months, and the operator may never see why pipeline is drying up.

A fourth failure is under-investing in palliative care as a feeder. Operators that run hospice-only motions miss the natural conversion stream from palliative patients who decline over 6-12 months. Optum, Aspire (Anthem), and Landmark have built large palliative care networks specifically to own the conversion path. Standalone hospices without a palliative arm face structurally lower MLOS because they only see patients in the final weeks.

A fifth failure is over-reliance on a single referral source. A hospice that draws 45%+ of admissions from one hospital is one chief medical officer change away from losing 30% of revenue. Healthy portfolios show no single source above 20% and the top 10 sources combining to 55-65% of admissions.

Reporting Cadence That Top Operators Actually Use

The daily standup at a well-run commercial hospice branch covers the census board: who admitted yesterday, who discharged, who is on continuous home care, who is in GIP. Liaisons report their referral count and any pending bedside visits. The branch director scans the days-from-referral aging.

Weekly territory reviews drill into RPM per liaison, conversion rate trends, and any referral source showing a drop versus the trailing 8-week average. A 25% week-over-week drop from a top-10 source triggers a same-day relationship intervention by the area VP.

Monthly business reviews look at MLOS segmented by diagnosis (the cap mix conversation), per-diem capture, and account penetration in each anchor hospital. The clinical and sales sides reconcile patients-on-service against the financial cap projection.

Quarterly reviews surface CAHPS top-box trends, live discharge rate, ADC growth versus market, and margin per patient day. These roll up to the C-suite at VITAS (Chemed earnings), Encompass, and increasingly to Optum Care leadership for Amedisys, LHC Group, and Compassus.

30/60/90 Day Plan for a New Hospice Sales Leader

Days 1-30: Listen and map the referral economy. Ride along with every liaison on the team for at least one full day each. Map the top 20 referral sources by admission volume over the trailing 12 months. Pull CAHPS Care Compare scores for your branches and the three nearest competitors. Identify any branch with MLOS under 35 days or cap utilization above 92% as immediate margin risk. Sit in on at least three family election meetings to understand the patient-side of the motion.

Days 31-60: Fix the broken accounts and the broken hires. Identify the 3-5 hospital accounts where penetration is under 15% and assign a clinical liaison to embed for 30 days. Coach or replace any liaison generating fewer than 12 RPM after a documented 60-day improvement plan. Stand up a daily 9 AM intake huddle to drive days-from-referral under 48 hours consistently. Begin a quarterly business review cadence with the top 10 referral sources, presenting CAHPS scores and clinical outcomes.

Days 61-90: Build the durable engine. Negotiate a preferred provider arrangement with at least one Medicare Advantage plan in your market for the hospice and palliative line. Launch or expand a palliative care service to feed long-cycle conversions. Stand up a CAHPS improvement task force targeting a 3-5 point lift in top-box recommend over the next two quarters. Set the 12-month plan with ADC growth, MLOS, and cap utilization targets approved by finance and clinical leadership jointly.

FAQ

Q1: What is the single most important KPI for a new hospice sales VP to fix first?

Referrals per Liaison per Month, with conversion rate as the immediate second. Everything downstream (ADC, revenue, MLOS) flows from the referral engine. A hospice with RPM under 15 will not grow regardless of clinical excellence.

Q2: How does Medicare Advantage change the hospice sales motion in 2027?

MA plans increasingly carve in hospice benefits and steer members to preferred provider networks. This shifts the buying decision from the hospital discharge planner toward the MA care management team. Operators without preferred network status in their major MA plans see referral volumes drop 20-30% over 12-18 months.

Q3: What is the difference between hospice and palliative care from a sales perspective?

Hospice requires a six-months-or-less terminal prognosis and replaces curative care; it is billed under the Medicare hospice per-diem benefit. Palliative care is curative-compatible, can run for years, and is billed under fee-for-service Medicare Part B or value-based MA contracts. Palliative is the feeder, hospice is the closer.

Q4: How do you balance the Medicare hospice aggregate cap with growth pressure?

Run a portfolio approach. Segment patients by diagnosis and expected MLOS. Cap utilization should sit at 75-85% blended. Operators who let cap utilization run above 92% face material clawback at year-end cost report. The discipline is admitting enough short-stay patients to offset the long-stay dementia and CHF tail without destroying admission-cost margin.

Q5: What CAHPS score should I target?

Top-box "willingness to recommend" of 85%+ keeps you competitive; 90%+ becomes a sales asset that liaisons can show discharge planners and physicians. Anything under 80% will quietly erode referrals over 6-12 months. Track it monthly even though CMS publishes quarterly.

Q6: How do private-equity and strategic acquirers value commercial hospice operators?

Acquirers like Optum (which bought Amedisys and LHC Group), Humana (which bought Kindred at Home and rebranded as CenterWell), and PE buyers like Webster Equity and Vistria typically value commercial hospice at 12-18x adjusted EBITDA, with premium paid for ADC scale, MLOS within the 50-75 day band, low cap exposure, and CAHPS top-quartile performance. Branches with structurally short MLOS or high cap utilization trade at meaningful discounts.

flowchart LR A[Hospital Discharge Planner Identifies Patient] --> B[Liaison Contacted] B --> C[Clinical Liaison Bedside Visit] C --> D[Physician Certification of Terminal Illness] D --> E[Family Meeting and Election] E --> F[Admission and Plan of Care] F --> G[Daily Per-Diem Billing to Medicare] G --> H[CAHPS Survey Post-Discharge] H --> I[Discharge Planner Feedback Loop] I --> A

flowchart TD A[Daily: Census, Admissions, Discharges, Referrals In] --> B[Weekly: RPM per Liaison, Conversion Rate, Days to Admission] B --> C[Monthly: MLOS by Diagnosis, Cap Utilization, Account Penetration] C --> D[Quarterly: CAHPS Top-Box, Live Discharge Rate, ADC Growth, Margin per Patient Day] D --> E[Annual: Cap Settlement, Cost Report, Network Status with MA Plans] E --> A

Related on PULSE

[Top 10 Hospice Care Revenue KPIs](/knowledge/ik0663)
[What are the key sales KPIs for the Commercial Carpet and Floor Care Services industry in 2027?](/knowledge/ik0046)
[What are the key sales KPIs for the Commercial Tree Care & Arboriculture industry in 2027?](/knowledge/ik0241)
[What are the key sales KPIs for the Commercial Dialysis and Renal Care industry in 2027?](/knowledge/ik0111)
[What are the key sales KPIs for the Commercial Urgent Care Center industry in 2027?](/knowledge/ik0106)
[What are the key sales KPIs for the Commercial Home Health Care industry in 2027?](/knowledge/ik0099)

Sources

Centers for Medicare and Medicaid Services (CMS), Hospice Care Compare and Public Use Files, 2025-2026 release cycle.
CMS Hospice Wage Index and Payment Rate Update Final Rule, FY2027 (per-diem rates and aggregate cap).
National Hospice and Palliative Care Organization (NHPCO), Facts and Figures, 2025 edition.
Chemed Corporation (VITAS Healthcare), Annual Report (Form 10-K) for FY2025 and quarterly investor presentations.
Enhabit Inc. (former Encompass hospice and home health), quarterly investor presentations, 2024-2025.
UnitedHealth Group / Optum Health Investor Day materials, 2024-2025 (Amedisys, LHC Group, Compassus integration).
Medicare Payment Advisory Commission (MedPAC), Report to Congress, March 2025 chapter on hospice services.
CAHPS Hospice Survey publicly reported results, CMS Care Compare, 2025-2026.

Download:

![What are the key sales KPIs for the Commercial Hospice and Palliative Care indus](https://saharahospicecare.com/wp-content/uploads/2023/04/Palliative-Care_Hospice-Care-Comparison.webp)

**What** are the key sales KPIs for the Commercial Hospice and Palliative Care industry in 2027?

## Direct Answer

![sales KPI dashboard on monitor](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20sales%20KPI%20dashboard%20on%20monitor%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=50239)

> **TL;DR:** Selling into commercial hospice and palliative care in 2027 is a referral-economy game wrapped inside Medicare reimbursement math. The nine KPIs that actually predict revenue are: (1) Referrals per Liaison per Month, (2) Referral-to-Admission Conversion Rate, (3) Median Length of Stay (MLOS), (4) Average Daily Census (ADC) Growth, (5) Per-Diem Capture Rate vs. CMS Cap, (6) Hospital Discharge Planner Account Penetration, (7) Live Discharge Rate, (8) Days from Referral to Admission, and (9) CAHPS Hospice Survey Score. Encompass Health, Amedisys, LHC Group, Compassus, Aveanna, Bristol Hospice, VITAS Healthcare, and Optum Care/SCAN Hospice all track variants of these. The median Medicare hospice MLOS sits near 92 days with a median of 18, per-diem routine home care reimburses about $221/day in 2027, and top liaisons generate 25-35 referrals per month with a 55-70% admission conversion. Miss these numbers and the unit economics collapse inside one quarter.

## Why Hospice and Palliative Care Sells Differently

![hospice liaison meeting with physician](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20hospice%20liaison%20meeting%20with%20physician%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=30924)


**Commercial** hospice and palliative care does not sell to the patient. It sells to the gatekeepers who decide where a dying or seriously ill patient spends their last weeks: hospital discharge planners, hospitalists, oncologists, skilled nursing facility (SNF) administrators, assisted living directors, and increasingly Medicare Advantage case managers. The patient and family are the end-user, but the deal closes in a hospital corridor or a physician office. That changes the entire revenue engine.

**Three** structural realities define the motion. First, payment is almost entirely Medicare under the per-diem hospice benefit, which means revenue is a function of admitted patient-days, not transaction price. Second, referrals are perishable. A discharge planner who hands off a patient on Tuesday wants a bed accepted by Wednesday morning or the patient routes to a competitor. Third, the aggregate cap on Medicare hospice reimbursement (around $34,500 per beneficiary in fiscal year 2027) forces operators to balance long-stay dementia and CHF patients against short-stay oncology patients to stay under the cap. Sales teams that ignore the cap mix end up clawing back revenue.

**The** buyer is rarely solo. A typical commercial hospice referral involves a hospitalist or attending physician signing the certification of terminal illness, a discharge planner or case manager coordinating the handoff, a hospice medical director accepting the patient, and a family meeting to confirm the election. Sales liaisons (the field title used by Amedisys, LHC Group, and VITAS) are the connective tissue. They live inside hospitals and SNFs, attend daily rounds, and own relationships with 8-15 referral sources each. The job is closer to medical device sales than SaaS. Pipeline is built one discharge planner relationship at a time, and a single hospital can swing 40+ admissions per month for the dominant provider.

**Palliative** care is the upstream feeder. Unlike hospice, palliative care is curative-compatible and bills under fee-for-service Medicare Part B plus increasingly under Medicare Advantage value-based contracts. Operators like Aspire Health (Anthem-owned), Optum's Landmark Health, and ChenMed's high-needs programs use palliative as a six-to-twelve-month relationship-building stage before a natural hospice conversion. The KPIs differ slightly (palliative tracks visit volume and per-member-per-month economics) but the referral physics are the same.

## The 9 KPIs That Actually Move the Number

![healthcare sales metrics chart](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20healthcare%20sales%20metrics%20chart%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=82566)


### 1. Referrals per Liaison per Month

**The** single best leading indicator of admissions 30 days out. Top-performing liaisons at VITAS Healthcare, Amedisys, and Compassus generate 25-35 qualified referrals per month. Median performers sit at 15-20. Below 12 and the territory is structurally unprofitable once you account for the fully-loaded liaison cost of roughly $135,000-$165,000 per year including base, commission, car allowance, and benefits.

**Benchmark**: 25-35/month elite, 15-20/month median, less than 12/month corrective action. Encompass Health publishes this internally as "RPM" (referrals per month) and runs weekly territory reviews against it.

### 2. Referral-to-Admission Conversion Rate

**Not** every referral becomes an admission. Patients die in transit, families decline, the hospitalist's prognosis was wrong, or the patient does not meet the six-months-or-less terminal certification. Industry median conversion sits at 55-65%. Best-in-class operators like Bristol Hospice and VITAS push 70-75% by deploying clinical liaisons (RN-credentialed) who can complete the face-to-face certification at the hospital bedside before discharge, removing a 24-48 hour handoff gap that loses patients.

**Benchmark**: 70%+ elite, 55-65% median, less than 50% indicates intake bottleneck or weak clinical screening at the front door.

### 3. Median Length of Stay (MLOS)

**The** financial heartbeat of any hospice. Medicare hospice MLOS nationally clusters at a median of 17-18 days with a mean near 92 days (the gap reflects the long tail of dementia and CHF patients). Commercial hospices target a MLOS of 45-75 days for unit economics to work. Below 30 days and the front-loaded admission costs (initial certification, medical equipment delivery, pharmacy onboarding) destroy margin. Above 90 days and cap exposure becomes a real risk.

**Benchmark**: 45-75 days target, less than 30 days margin-destructive, more than 90 days cap risk. Amedisys (now part of Optum/UnitedHealth Group) reports this segmented by diagnosis category each quarter.

### 4. Average Daily Census (ADC) Growth

ADC is the rolling count of patients on service on any given day. It is the revenue multiplier: ADC times per-diem times days equals revenue. Healthy commercial hospices grow ADC 8-15% year over year in stable markets and 20-30% in expansion markets. LHC Group historically reported ADC growth as a primary investor metric pre-Optum acquisition. A flat or declining ADC for two consecutive quarters in a market means the referral engine is breaking.

**Benchmark**: 10%+ YoY growth healthy, 5-10% mature market, less than 5% or negative indicates competitive loss.

### 5. Per-Diem Capture Rate vs. CMS Cap

**The Medicare** hospice benefit pays four per-diem rates: Routine Home Care (RHC, around $221/day in FY2027 for the first 60 days then about $174/day after), Continuous Home Care (about $1,640/day), Inpatient Respite (about $510/day), and General Inpatient (GIP, about $1,165/day). The aggregate cap per beneficiary sits near $34,500 in 2027. Operators track "cap utilization" - how close their average revenue per patient sits to the cap ceiling. Best operators run at 75-85% cap utilization, leaving room for the long-stay outliers without triggering clawback.

**Benchmark**: 75-85% cap utilization optimal, more than 95% triggers clawback risk, less than 65% means leaving revenue on the table or admitting too-short-stay patients.

### 6. Hospital Discharge Planner Account Penetration

**Measured** as the share of a hospital's hospice-eligible discharges that route to your service. In a hospital with 50 hospice-appropriate discharges per month, capturing 18 of them is a 36% penetration rate. Dominant providers in a market hold 40-55% penetration in their anchor hospitals. Compassus and VITAS Healthcare both run "anchor hospital" strategies where they assign two liaisons to a single high-volume facility and target 50%+ penetration before expanding to secondary accounts.

**Benchmark**: 40%+ in anchor hospitals, 20-30% in secondary accounts, less than 15% means the account is not yet truly worked.

### 7. Live Discharge Rate

**Patients** who leave hospice alive - either because they revoked the benefit, transferred, or were discharged for extended prognosis. The national median sits near 17-19%. A live discharge rate above 25% draws Medicare audit attention and suggests the admission screening is too loose (patients admitted who were not truly terminal). Below 10% may indicate the opposite: refusing borderline patients and missing referrals. CMS publishes this on Care Compare and Medicare Advantage payers increasingly use it to deselect providers from preferred networks.

**Benchmark**: 12-18% acceptable, more than 25% audit risk, less than 10% may indicate over-tight admission gating.

### 8. Days from Referral to Admission

**Time** from receiving a referral to the patient being on service. Elite operators close this in less than 24 hours for hospital discharges and less than 48 hours for community referrals. Every day of delay loses roughly 15-20% of referrals to competitors or patient deaths. Bristol Hospice publishes a 24-hour admission guarantee in many markets. Aveanna Healthcare's hospice division reports same-day admission rates as a board-level metric.

**Benchmark**: less than 24 hours for hospital referrals elite, 24-48 hours acceptable, more than 72 hours severely lossy.

### 9. CAHPS Hospice Survey Score

**The Consumer Assessment** of Healthcare Providers and Systems (CAHPS) hospice family survey is publicly reported by CMS and increasingly tied to Medicare Advantage network status. The composite "Rating of Hospice" score (0-10 scale) and the "Willingness to Recommend" percentage both influence physician and discharge planner referral patterns. Top quartile providers post 87-92% top-box willingness-to-recommend. Below 80% and physicians quietly steer referrals elsewhere.

**Benchmark**: 85%+ top-box recommend elite, 80-85% middle, less than 80% referral-eroding.

```mermaid
flowchart LR
    A[Hospital Discharge Planner Identifies Patient] --> B[Liaison Contacted]
    B --> C[Clinical Liaison Bedside Visit]
    C --> D[Physician Certification of Terminal Illness]
    D --> E[Family Meeting and Election]
    E --> F[Admission and Plan of Care]
    F --> G[Daily Per-Diem Billing to Medicare]
    G --> H[CAHPS Survey Post-Discharge]
    H --> I[Discharge Planner Feedback Loop]
    I --> A
```

## Real Operators and How They Track These KPIs

**Amedisys (Optum/UnitedHealth Group)** runs one of the largest commercial hospice footprints in the country with operations across 35+ states. Post-acquisition by Optum in 2024, Amedisys integrated its hospice referral engine with UnitedHealthcare Medicare Advantage member panels, creating a captive referral channel alongside its hospital-based liaison team. Internal reporting tracks RPM, conversion rate, and MLOS by branch weekly.

**Encompass Health** spun off its hospice and home health business as Enhabit in 2022, but the parent Encompass inpatient rehab division continues to be one of the largest single sources of hospice referrals nationally (rehab patients who do not meet discharge criteria often convert to palliative or hospice). Enhabit reports ADC, MLOS, and adjusted EBITDA per patient day quarterly to investors.

**LHC Group (Optum)** was acquired by Optum in 2023. Pre-acquisition LHC reported hospice ADC growth, admissions per branch, and cost per patient day as primary metrics. Post-acquisition, hospice operates inside Optum Care's value-based care portfolio alongside palliative care and home health.

**Compassus** is the largest privately-held US hospice provider, with a major OptumHealth ownership stake taken in 2024. Compassus runs an anchor-hospital sales model with embedded liaisons in 200+ acute care facilities. Internal scorecards weight RPM, conversion rate, and CAHPS top-box recommend equally.

**Aveanna Healthcare** entered hospice through its 2021 acquisition of Comfort Care Hospice and has grown the segment through tuck-in deals. Aveanna's hospice unit reports referral-to-admission velocity (days from referral) as a board-level metric because its pediatric home health heritage trained the operating team on speed-of-acceptance.

**Bristol Hospice** is a private-equity-backed (Webster Equity, then Vistria Group) commercial hospice with 35+ locations across 16 states. Bristol's growth model is built on 24-hour admission guarantees, dedicated clinical liaisons (RNs) at anchor hospitals, and aggressive CAHPS performance. Internal RPM targets sit at 28-32 referrals per liaison per month.

**VITAS Healthcare (Chemed Corporation)** is the largest single-brand US hospice with roughly 18,000+ ADC and operations in 14 states plus DC. VITAS pioneered the inpatient hospice unit model and runs a dedicated continuous home care service line. Public Chemed filings report ADC growth, admissions, MLOS, and cap utilization quarterly.

**Optum Care / SCAN Hospice** represents the new Medicare Advantage-aligned hospice model. With SCAN Health Plan and Optum both building captive hospice networks for their MA members, the sales motion shifts from hospital discharge planners to MA care managers and value-based care contracts. KPIs add per-member-per-month palliative spend and total cost of care for the final 90 days of life.

## Failure Modes: How Hospice Sales Teams Miss the Number

**The** most common failure is treating hospice like a transactional B2B sale. Hospice is a relationship business where the same discharge planner sends 40 referrals over 18 months or sends zero. New sales leaders who push liaisons to "make more calls" without protecting the quality-of-presence time inside the hospital see referral volumes drop within a quarter. Liaison turnover is the silent killer: each lost liaison resets 6-9 months of relationship equity in a territory.

A second failure is mismatched patient mix. Commercial hospices that take too many short-stay oncology referrals (MLOS under 15 days) destroy margin on admission costs. Those that load up on long-stay dementia and CHF patients without segmenting by cap exposure end up with clawback liability at the cost report. The right mix targets a blended MLOS of 55-70 days with cap utilization at 78-82%.

A third failure is ignoring CAHPS. Operators who treat the CAHPS family survey as a compliance checkbox rather than a sales asset miss the fact that hospital discharge planners and oncologists actively look up Care Compare scores. A 78% top-box recommend score versus a competitor's 90% will quietly route referrals away over 6-12 months, and the operator may never see why pipeline is drying up.

A fourth failure is under-investing in palliative care as a feeder. Operators that run hospice-only motions miss the natural conversion stream from palliative patients who decline over 6-12 months. Optum, Aspire (Anthem), and Landmark have built large palliative care networks specifically to own the conversion path. Standalone hospices without a palliative arm face structurally lower MLOS because they only see patients in the final weeks.

A fifth failure is over-reliance on a single referral source. A hospice that draws 45%+ of admissions from one hospital is one chief medical officer change away from losing 30% of revenue. Healthy portfolios show no single source above 20% and the top 10 sources combining to 55-65% of admissions.

## Reporting Cadence That Top Operators Actually Use

```mermaid
flowchart TD
    A[Daily: Census, Admissions, Discharges, Referrals In] --> B[Weekly: RPM per Liaison, Conversion Rate, Days to Admission]
    B --> C[Monthly: MLOS by Diagnosis, Cap Utilization, Account Penetration]
    C --> D[Quarterly: CAHPS Top-Box, Live Discharge Rate, ADC Growth, Margin per Patient Day]
    D --> E[Annual: Cap Settlement, Cost Report, Network Status with MA Plans]
    E --> A
```

**The** daily standup at a well-run commercial hospice branch covers the census board: who admitted yesterday, who discharged, who is on continuous home care, who is in GIP. Liaisons report their referral count and any pending bedside visits. The branch director scans the days-from-referral aging.

**Weekly** territory reviews drill into RPM per liaison, conversion rate trends, and any referral source showing a drop versus the trailing 8-week average. A 25% week-over-week drop from a top-10 source triggers a same-day relationship intervention by the area VP.

**Monthly** business reviews look at MLOS segmented by diagnosis (the cap mix conversation), per-diem capture, and account penetration in each anchor hospital. The clinical and sales sides reconcile patients-on-service against the financial cap projection.

**Quarterly** reviews surface CAHPS top-box trends, live discharge rate, ADC growth versus market, and margin per patient day. These roll up to the C-suite at VITAS (Chemed earnings), Encompass, and increasingly to Optum Care leadership for Amedisys, LHC Group, and Compassus.

## 30/60/90 Day Plan for a New Hospice Sales Leader

**Days 1-30: Listen and map the referral economy.** Ride along with every liaison on the team for at least one full day each. Map the top 20 referral sources by admission volume over the trailing 12 months. Pull CAHPS Care Compare scores for your branches and the three nearest competitors. Identify any branch with MLOS under 35 days or cap utilization above 92% as immediate margin risk. Sit in on at least three family election meetings to understand the patient-side of the motion.

**Days 31-60: Fix the broken accounts and the broken hires.** Identify the 3-5 hospital accounts where penetration is under 15% and assign a clinical liaison to embed for 30 days. Coach or replace any liaison generating fewer than 12 RPM after a documented 60-day improvement plan. Stand up a daily 9 AM intake huddle to drive days-from-referral under 48 hours consistently. Begin a quarterly business review cadence with the top 10 referral sources, presenting CAHPS scores and clinical outcomes.

**Days 61-90: Build the durable engine.** Negotiate a preferred provider arrangement with at least one Medicare Advantage plan in your market for the hospice and palliative line. Launch or expand a palliative care service to feed long-cycle conversions. Stand up a CAHPS improvement task force targeting a 3-5 point lift in top-box recommend over the next two quarters. Set the 12-month plan with ADC growth, MLOS, and cap utilization targets approved by finance and clinical leadership jointly.

## FAQ

**Q1: What is the single most important KPI for a new hospice sales VP to fix first?**

**Referrals** per Liaison per Month, with conversion rate as the immediate second. Everything downstream (ADC, revenue, MLOS) flows from the referral engine. A hospice with RPM under 15 will not grow regardless of clinical excellence.

**Q2: How does Medicare Advantage change the hospice sales motion in 2027?**

MA plans increasingly carve in hospice benefits and steer members to preferred provider networks. This shifts the buying decision from the hospital discharge planner toward the MA care management team. Operators without preferred network status in their major MA plans see referral volumes drop 20-30% over 12-18 months.

**Q3: What is the difference between hospice and palliative care from a sales perspective?**

**Hospice** requires a six-months-or-less terminal prognosis and replaces curative care; it is billed under the Medicare hospice per-diem benefit. Palliative care is curative-compatible, can run for years, and is billed under fee-for-service Medicare Part B or value-based MA contracts. Palliative is the feeder, hospice is the closer.

**Q4: How do you balance the Medicare hospice aggregate cap with growth pressure?**

**Run** a portfolio approach. Segment patients by diagnosis and expected MLOS. Cap utilization should sit at 75-85% blended. Operators who let cap utilization run above 92% face material clawback at year-end cost report. The discipline is admitting enough short-stay patients to offset the long-stay dementia and CHF tail without destroying admission-cost margin.

**Q5: What CAHPS score should I target?**

**Top**-box "willingness to recommend" of 85%+ keeps you competitive; 90%+ becomes a sales asset that liaisons can show discharge planners and physicians. Anything under 80% will quietly erode referrals over 6-12 months. Track it monthly even though CMS publishes quarterly.

**Q6: How do private-equity and strategic acquirers value commercial hospice operators?**

**Acquirers** like Optum (which bought Amedisys and LHC Group), Humana (which bought Kindred at Home and rebranded as CenterWell), and PE buyers like Webster Equity and Vistria typically value commercial hospice at 12-18x adjusted EBITDA, with premium paid for ADC scale, MLOS within the 50-75 day band, low cap exposure, and CAHPS top-quartile performance. Branches with structurally short MLOS or high cap utilization trade at meaningful discounts.

<!--pillar-weave-->
## Related on PULSE

- [Top 10 Hospice Care Revenue KPIs](/knowledge/ik0663)
- [What are the key sales KPIs for the Commercial Carpet and Floor Care Services industry in 2027?](/knowledge/ik0046)
- [What are the key sales KPIs for the Commercial Tree Care & Arboriculture industry in 2027?](/knowledge/ik0241)
- [What are the key sales KPIs for the Commercial Dialysis and Renal Care industry in 2027?](/knowledge/ik0111)
- [What are the key sales KPIs for the Commercial Urgent Care Center industry in 2027?](/knowledge/ik0106)
- [What are the key sales KPIs for the Commercial Home Health Care industry in 2027?](/knowledge/ik0099)

## Sources

- Centers for Medicare and Medicaid Services (CMS), Hospice Care Compare and Public Use Files, 2025-2026 release cycle.
- CMS Hospice Wage Index and Payment Rate Update Final Rule, FY2027 (per-diem rates and aggregate cap).
- National Hospice and Palliative Care Organization (NHPCO), Facts and Figures, 2025 edition.
- Chemed Corporation (VITAS Healthcare), Annual Report (Form 10-K) for FY2025 and quarterly investor presentations.
- Enhabit Inc. (former Encompass hospice and home health), quarterly investor presentations, 2024-2025.
- UnitedHealth Group / Optum Health Investor Day materials, 2024-2025 (Amedisys, LHC Group, Compassus integration).
- Medicare Payment Advisory Commission (MedPAC), Report to Congress, March 2025 chapter on hospice services.
- CAHPS Hospice Survey publicly reported results, CMS Care Compare, 2025-2026.

Was this helpful?

⌬ Apply this in PULSE

Gross Profit CalculatorModel margin per deal, per rep, per territory

Deep dive · related in the library

pulse-aquariums · aquariumTop 10 Canister Filters 2027 pulse-aquariums · aquariumTop 10 Hang-On-Back Aquarium Filters 2027 pulse-aquariums · aquariumTop 10 Aquarium Filters 2027 pulse-industry-kpis · industry-kpisThe Best KPIs for Self-Storage Facilities in 2027 pulse-industry-kpis · industry-kpisWhat are the most important KPIs every dermatology practice should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every escape room should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every laundromat should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every dog boarding and daycare business should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every campground should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every winery should track in 2027?